August 29, 2017

Brain PET scans change management of patients with possible Alzheimer’s

Michael J. Pontecorvo, PhD, of Eli Lilly’s Avid Radiopharmaceuticals and colleagues at numerous medical institutions sent 618 patients for florbetapir (18F) PET neuroimaging, then randomized them 1:1 for amyloid assessment either immediately (information group) or after one year (control group). {read more here}